International: +1-347-960-6455
Nuclear Factor Kappa-Light-Chain-Enhancer of Activated B Cells (NF-κB) Inhibitors Pipeline to Witness Significant Growth due to Increased Number of Pipeline Candidates by Drug Developers

According to a new research report Nuclear Factor Kappa-Light-Chain-Enhancer of Activated B Cells (NF-κB) Inhibitors – Pipeline Analysis 2019, Clinical Trials and Results, Patents, Designations, Collaborations, and Other Developments” published by Pharma Proff, NF-κB inhibitors currently exhibit a proliferating pipeline with 10+ therapeutic candidates.

NF-κB Inhibitors Pipeline Insights

NF-κB is a family of transcription factors, aiding many regulatory cellular functions such as regulation of apoptosis, inflammatory responses, cellular growth, and others. Cancer, arthritis, and asthma are some of the diseases caused by NF-κB. It transcribes various genes, and this transcription depends on post translational modifications (PTMs), and composition of NF-κB in the nucleus. Phosphorylation of NF-κB inhibitors followed by their ubiquitination and degradation leads to activation of NF-κB.

Insights into Pipeline Segments

According to the research, drugs being developed as NF-κB inhibitors, most of which are in clinical phases and can be expected to be given orally. It has been found that the oral route of administration is convenient, economical, non-invasive, and inexpensive in nature.

Technological Advancements Play a Pivotal Role in NF-κB Inhibitors Development

Collaborations and various strategic developments among companies are taking place in the wake of technological developments. For instance, in 2012, Cleveland Bio Labs and Incuron Inc. together announced orphan drug status of CBL0102 for hepatocellular carcinoma. This drug ought to involve NF-κB inhibitors to control the disease. Moreover, in April 2013, AnGes MG Inc. and Shionogi & Co. Ltd. agreed to start phase I clinical trial for atopic dermatitis. Additionally, in September 2014, Reata Pharmaceuticals Incorporated announced completion of recruitment in phase I trial of RTA 408 for lung carcinoma, which functions by inhibiting NF-κB.

Browse Detailed Report at:

Alkermes plc, Incuron Inc., Catabasis Pharmaceuticals Inc., Reata Pharmaceuticals Inc., and Cleveland Bio Labs are some of the companies involved in development of NF-κB inhibitors.

NF-κB Inhibitors Pipeline Analysis

  • By Phase
  • By Molecule Type
  • By Route of Administration
  • By Company

The report comprises detailed pipeline analysis of NF-κB Inhibitors under development. Comprehensive insights on the pipeline products have been provided, with special focus on strategic developments of key players, information on drug licensing, designations, financing, and grants, technological advancements, patents, and upcoming conferences. In addition, the report highlights the winning strategies of companies involved in the development of NF-κB inhibitors. Detailed regulatory approval procedures in the U.S., Europe, and Japan are also provided in this report. Furthermore, the report contains competitive analysis and extensive information on monotherapies, combination therapies, targets and mechanisms of action, and drug origin with respect to NF-κB Inhibitors.